Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 13/20 | 1.00 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8556044 | 0.95 | ITGB3 (0.90) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 | |
| SCHEMBL8558560 | 0.91 | ITGB3 (0.82) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 | |
| Trifluoroacetic Acid SCHEMBL8554757 | 0.90 | ITGB3 (0.90) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 | |
| SCHEMBL29357180 | 0.89 | ITGB3 (0.80) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 | |
| Trifluoroacetic Acid SCHEMBL8558868 | 0.89 | ITGB3 (0.80) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 | |
| SCHEMBL29380494 | 0.89 | ITGB3 (0.80) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 | |
| Trifluoroacetic Acid SCHEMBL8553811 | 0.89 | ITGB3 (0.79) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 | |
| Trifluoroacetic Acid SCHEMBL8553208 | 0.88 | ITGB3 (0.90) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 | |
| Trifluoroacetic Acid SCHEMBL8557188 | 0.88 | ITGB3 (0.78) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 | |
| Trifluoroacetic Acid SCHEMBL8558553 | 0.88 | ITGB3 (0.78) | ITGB3ITGA2BTPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0641770-B1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA CO (JP) | 1998-05-13 | — | — | EP | claimed |
| US-20230190690-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | NEOPHARMA JAPAN CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-115768415-A | Novel therapeutic and/or prophylactic agent for coronavirus infection (COVID-19) | 日本纽翱医药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4140479-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | Neopharma Japan Co., Ltd. (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-6472397-B1 | Nitrogen-containing heterocyclic compounds having antiplatelet aggregation effect and medicinal use thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-29 | — | — | US | disclosed |
| EP-1070712-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING ANTIPLATELET AGGREGATION EFFECT AND MEDICINAL USE THEREOF | MEIJI SEIKA KAISHA LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-0641770-B1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA CO (JP) | 1998-05-13 | — | — | EP | disclosed |
| US-5594004-A | CARDIOVASCULAR DISORDERS AND ANTICOAGULANTS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0641770-A1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190690-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | ACE, ACE2, IL5 | ITGB3 3548/4885ITGA2B 3713/4885TPSAB1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.